Acute graft-versus-host disease

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30-50% of patients who receive stem cell products from HLA-identical siblings will develop grades 2-4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70%. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient's response to initial treatment.

Original languageEnglish (US)
Title of host publicationBlood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care
PublisherSpringer New York
Pages167-187
Number of pages21
ISBN (Print)9781441975058
DOIs
StatePublished - 2011

Fingerprint

Graft vs Host Disease
Histocompatibility Testing
Unrelated Donors
Siblings
Stem Cells
Morbidity
Transplants
Mortality
Therapeutics
TimeLine
Transplant Recipients

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Slater, S. (2011). Acute graft-versus-host disease. In Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care (pp. 167-187). Springer New York. https://doi.org/10.1007/978-1-4419-7506-5_15

Acute graft-versus-host disease. / Slater, Susan.

Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer New York, 2011. p. 167-187.

Research output: Chapter in Book/Report/Conference proceedingChapter

Slater, S 2011, Acute graft-versus-host disease. in Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer New York, pp. 167-187. https://doi.org/10.1007/978-1-4419-7506-5_15
Slater S. Acute graft-versus-host disease. In Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer New York. 2011. p. 167-187 https://doi.org/10.1007/978-1-4419-7506-5_15
Slater, Susan. / Acute graft-versus-host disease. Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer New York, 2011. pp. 167-187
@inbook{035fe3a545394685bb54a4f9805b571e,
title = "Acute graft-versus-host disease",
abstract = "Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30-50{\%} of patients who receive stem cell products from HLA-identical siblings will develop grades 2-4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70{\%}. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient's response to initial treatment.",
author = "Susan Slater",
year = "2011",
doi = "10.1007/978-1-4419-7506-5_15",
language = "English (US)",
isbn = "9781441975058",
pages = "167--187",
booktitle = "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care",
publisher = "Springer New York",

}

TY - CHAP

T1 - Acute graft-versus-host disease

AU - Slater, Susan

PY - 2011

Y1 - 2011

N2 - Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30-50% of patients who receive stem cell products from HLA-identical siblings will develop grades 2-4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70%. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient's response to initial treatment.

AB - Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30-50% of patients who receive stem cell products from HLA-identical siblings will develop grades 2-4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70%. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient's response to initial treatment.

UR - http://www.scopus.com/inward/record.url?scp=84892320779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892320779&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7506-5_15

DO - 10.1007/978-1-4419-7506-5_15

M3 - Chapter

AN - SCOPUS:84892320779

SN - 9781441975058

SP - 167

EP - 187

BT - Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care

PB - Springer New York

ER -